Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (3622)	8/25/1999 8:30:00 AM
From: BMcV	of 10280

One positive aspect of this collaboration is that it shows J&J views GI as a therapeutic area they wish to target, which bodes well for noracisapride. >>In announcing the approval, David Norton, president of Janssen U.S., said, ''Aciphex represents the newest advance in PPI therapies and is an important product for Janssen. It complements our GI franchise and will be another building block for the growth of this company.''<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next